Emerging Dangers of Hexahydrocannabinol (HHC) in Youth: A Call for Action

Recent reports from healthcare professionals have raised alarms about the rise of synthetic cannabinoids being sold in vape shops, specifically focusing on hexahydrocannabinol (HHC). This substance is increasingly linked to serious psychological issues, including psychotic episodes, particularly among young users, some of whom are as young as 13 years old.

The Scope of the Problem

Professor Bobby Smyth, a child and adolescent psychiatrist from Trinity College Dublin, highlighted that 20-25% of presentations to adolescent addiction services now involve HHC. This figure has surged from virtually zero reports just 18 months prior, indicating a rapid increase in use and its associated problems.

Emerging Patterns of HHC Use

Since the emergence of HHC in youth addiction and mental health services approximately 14 months ago, professionals have noted a consistent escalation in cases each month. Concerns highlight that the perception of safety surrounding these products is misleading, as they are often sold in shops without proper testing or regulation. Since HHC falls into a legal gray area—neither classified as a health product nor a food product—it escapes oversight by the Health Products Regulatory Authority (HPRA) and the Food Safety Authority (FSA).

Legislative Gaps

Despite prior legislative efforts, particularly the Criminal Justice Psychoactive Substances Act 2010 which aimed to curb the sale of psychoactive substances, newer synthetic products like HHC have emerged, exploiting loopholes. The act effectively closed many “headshops” that sold synthetic drugs, but the loosely defined language allowed for new chemical formulations to slip through regulatory cracks.

Impact on Young Minds

According to Mick Finn, a youth services manager and the former lord mayor of Cork City, young individuals are increasingly entering hospitals due to severe psychotic reactions from HHC vape use. Symptoms reported include paranoia, severe mood swings, aggressive behavior, and heightened anxiety. Shockingly, one-third of young people in certain youth services are misusing HHC and experiencing debilitating mental health issues.

Long-Term Risks

Prof. Smyth warns that psychiatric illnesses resulting from HHC may result in long-term and irreversible damage to young people’s mental health. He advocates for immediate action to eliminate HHC products from the market to prevent these avoidable consequences.

A Call for Regulation

Concerns voiced by both health professionals and community leaders highlight the urgent need for a reevaluation of the existing regulatory framework to ensure that dangerous substances like HHC are not easily accessible to minors. The rise in psychotic episodes and potential links to suicidal behavior among users underscores the critical need for controls similar to those established for previously banned substances.

Research and Monitoring

Research conducted by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in May 2022 categorized HHC as a substance of concern, leading to intensified monitoring. Health professionals stress the importance of awareness regarding the unpredictable composition of synthetic cannabinoids, as they often do not contain THC but may involve other more dangerous synthetic variations, heightening the risk of drug emergencies.

Conclusion

The insight from mental health professionals like Prof. Smyth and community leaders illustrates a pressing issue that requires immediate attention and action from regulatory bodies. The commercialization of dangerous substances without adequate checks and balances poses an alarming threat to public health, particularly among the youth population, who increasingly bear the consequences.